Bolt Biotherapeutics has acquired Prana Therapies, gaining access to Prana's pipeline of next-generation multispecific antibodies, including PRA-216, a novel bispecific antibody in Phase 2 trials for asthma, COPD, atopic dermatitis, and planned studies in eosinophilic esophagitis. The acquisition was accompanied by a $120 million private placement financing, with potential for an additional $60 million, to fund operations into 2028. Sheila Gujrathi, Prana's co-founder, joins Bolt's executive team and board. Patient data from PRA-216's four Phase 2 trials is expected starting Q2 2027, marking a significant step in developing treatments for multiple inflammatory diseases.
Bolt Biotherapeutics acquisition news is context for readers following health stocks. Of 150 priced US health stocks on Pluang, 31 rose and 112 fell today. Notable movers include Cytokinetics Inc at USD 63.20 (+1.40%), Inovio Pharmaceuticals Inc at USD 0.85 (+1.32%), and Sana Biotechnology Inc at USD 2.40 (+1.27%). Data is as of Oct 23, 2026 18:41 WIB.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
